Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2%

Exicure, Inc. (NASDAQ:XCUR) saw a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 28,200 shares, a growth of 24.2% from the February 13th total of 22,700 shares. Currently, 7.4% of the shares of the stock are short sold. Based on an average daily volume of 106,200 shares, the short-interest ratio is currently 0.3 days.

Exicure Stock Performance

Shares of XCUR opened at $12.99 on Tuesday. The company’s fifty day moving average is $10.28 and its 200 day moving average is $9.31. Exicure has a fifty-two week low of $1.44 and a fifty-two week high of $36.00. The stock has a market capitalization of $33.85 million, a PE ratio of -6.28 and a beta of 3.84.

Institutional Investors Weigh In On Exicure

An institutional investor recently raised its position in Exicure stock. Carlyle Group Inc. raised its position in shares of Exicure, Inc. (NASDAQ:XCUR) by 400.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 281,636 shares of the company’s stock after acquiring an additional 225,308 shares during the period. Exicure makes up about 0.9% of Carlyle Group Inc.’s investment portfolio, making the stock its 11th largest position. Carlyle Group Inc. owned 10.79% of Exicure worth $3,850,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.82% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.